CRISPR Makes History: One Injection Ends Hereditary Angioedema

For decades, patients with hereditary angioedema lived under the shadow of unpredictable, potentially fatal swelling episodes that could strike at any moment. Now, in vivo CRISPR gene editing has achieved something the medical world has never witnessed: a successful Phase 3 clinical trial proving that a single injection can permanently alter a patient’s DNA to prevent disease. Published simultaneously in the New England Journal of Medicine, Intellia Therapeutics’ therapy lonvo-z reduced HAE attacks by 87% compared to placebo — with the majority of patients experiencing zero attacks over six consecutive months. It is the first time gene editing inside a living human body has cleared the highest bar in clinical medicine.

What Is Hereditary Angioedema — and Why Is It So Hard to Treat?

Hereditary angioedema (HAE) is a rare genetic disorder affecting roughly 1 in 50,000 people worldwide. Caused by deficiency or dysfunction of the C1 inhibitor protein (encoded by the SERPING1 gene), HAE triggers overproduction of bradykinin — a peptide that dramatically increases vascular permeability. The result is episodes of painful, potentially fatal swelling in the limbs, gastrointestinal tract, and — most dangerously — the larynx. Before modern therapies, laryngeal HAE attacks carried a mortality rate exceeding 30%. Today’s best treatments require frequent self-injections, often multiple times per month, providing only temporary suppression of the underlying biology. The dream of a one-time cure has driven researchers for years, and in vivo gene editing promised to deliver it — but the leap from phase 1 to phase 3 proof has taken over a decade.

How In Vivo CRISPR Gene Editing Silences the Kallikrein Cascade

The therapy targets the root mechanism with surgical precision. HAE attacks are set in motion by plasma kallikrein, an enzyme encoded by the KLKB1 gene predominantly in the liver. Kallikrein catalyzes the cleavage of high-molecular-weight kininogen into bradykinin — the molecule that makes blood vessels dangerously leaky. Lonvo-z delivers a CRISPR-Cas9 gene-editing complex directly into hepatocytes via lipid nanoparticles (LNPs) — the same vehicle technology that powered COVID-19 mRNA vaccines. Once inside liver cells, the Cas9 enzyme cuts the KLKB1 gene, permanently disabling kallikrein production at the genomic level. With plasma kallikrein silenced, the bradykinin cascade cannot be triggered, and attacks are eliminated at their source. The entire intervention consists of a single 50 mg intravenous infusion — no follow-up doses, no maintenance medication, no ongoing treatment required.

The HAELO Trial: Eighty Patients, One Historic Result

The Phase 3 HAELO trial enrolled 80 patients aged 16 and older with Type I or Type II hereditary angioedema. Participants received either lonvo-z (n=52) or placebo (n=28) as a single intravenous infusion, then were monitored for 28 weeks. The results were unambiguous. During the six-month primary efficacy period, the lonvo-z group recorded a mean monthly attack rate of 0.26 attacks against 2.10 attacks in the placebo group — an 87% relative reduction (p < 0.0001). Even more striking: 62% of lonvo-z patients remained completely attack-free throughout the entire observation period, compared to just 11% of placebo patients. The safety profile was reassuring — the most common adverse events were mild infusion-related reactions, headache, and fatigue, with no serious adverse events recorded in the lonvo-z arm. These results were simultaneously presented at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 congress and published in the New England Journal of Medicine.

A New Era: What In Vivo CRISPR Gene Editing Changes for Medicine

The success of lonvo-z represents far more than a treatment for one rare disease. It is proof-of-concept that in vivo CRISPR gene editing — editing genes inside a living patient’s body rather than in a laboratory dish — can clear the highest bar in clinical medicine. Intellia has already initiated a rolling Biologics License Application (BLA) with the FDA, targeting a commercial launch in H1 2027. If approved, lonvo-z would become the first in vivo CRISPR therapy ever authorised for use in humans — a milestone as consequential as the first approval of recombinant insulin in 1982.

The implications extend well beyond HAE. The lipid nanoparticle delivery platform used by lonvo-z is already being evaluated by Intellia for a growing pipeline of liver-targeting gene edits: transthyretin amyloidosis, complement-mediated diseases, and inherited clotting disorders. Each successful application adds engineering confidence and regulatory precedent that will accelerate the next generation of therapies. Analysts project the in vivo gene editing market could exceed $15 billion by 2035, driven by applications across cardiovascular disease, inherited metabolic conditions, and oncology.

Cost and access will be the next frontier. One-time curative therapies — like approved haemophilia gene therapies — have set precedents in the $2–4 million range per patient, raising immediate questions about payer sustainability. The scientific problem appears solved; the economic and systemic challenges are just beginning. Yet the trajectory is clear: for diseases driven by a single malfunctioning gene in the liver, lonvo-z has established the template for permanent, single-dose correction.

What makes this moment philosophically remarkable is permanence. Unlike chronic medications, lonvo-z does not manage symptoms — it eliminates the molecular trigger by rewriting the genome. For HAE patients who have endured decades of preventive injections, emergency room visits, and the constant anxiety of an unpredictable attack, a single infusion offering lasting freedom is not merely a medical achievement — it is a transformation of what it means to live with a genetic disease. In vivo CRISPR gene editing has crossed from compelling theory to incontrovertible proof. The question is no longer whether this technology works. The question is how quickly medicine, regulators, and health systems can build the infrastructure to deliver it at scale.